Evolving Research Landscape Drives Progress in CLE at AAD 2026

Cutaneous lupus erythematosus (CLE) is a disease whose therapeutic stagnation has stood in stark contrast to the scientific progress made in understanding its underlying biology. Over the past two decades, advances in immunology have illuminated the central role of plasmacytoid dendritic cells, type I interferon signaling, and innate immune dysregulation in driving the skin inflammation, tissue injury, and scarring that define the disease.¹ That growing mechanistic clarity has not only reframed how clinicians think about CLE pathophysiology but has begun to translate into a new generation of rationally designed therapeutic candidates targeting the specific immunological pathways responsible for disease activity.

Litifilimab is perhaps the clearest example of that translation. Its development as a BDCA2-targeting monoclonal antibody was predicated on the understanding that pDC-driven type I interferon production is a proximal driver of lupus pathogenesis, and its two positive Phase 2 trials in CLE represent the most advanced clinical validation of that mechanistic hypothesis to date.² The progress made in CLE is also inseparable from broader advances in lupus research, where a deepening understanding of immune dysregulation across the spectrum of disease has created shared scientific infrastructure that benefits both systemic and cutaneous manifestations.

For patients who have lived with inadequate treatment options for generations, the convergence of scientific understanding and clinical evidence now underway represents a genuine inflection point. In this final segment, Joseph Merola, MD, MMSc, and Victoria Werth, MD, reflect on how the field's evolving understanding of CLE pathophysiology has shaped the current moment in drug development, and what the trajectory of innovation suggests for the future of care in this long-underserved disease.

References

1. Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359-1371. doi:10.1172/JCI124466
2. Biogen Inc. Biogen announces second positive Phase 2 litifilimab trial in cutaneous lupus erythematosus at 2026 American Academy of Dermatology Annual Meeting, showing a significant reduction in skin disease activity. Published March 28, 2026. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial